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Heart failure (HF) is a complex clinical syndrome
that can result from any structural or functional cardiac
disorder that impairs the ability of the ventricle to fill
with or eject blood. It results from coronary artery
disease in about two-thirds of patients; the remainder
have non-ischemic cardiomyopathy, the cause of which
may be known (e.g., hypertension, valvular disease,
or myocarditis) or unknown (e.g., idiopathic dilated
cardiomyopathy). A relatively common disorder, HF
is estimated to affect nearly 5,000,000 people in the
U.S., with about 550,000 new patients each year.
Morbidity and mortality rates are high: each year in
the U.S., HF results in approximately 970,000
hospitalizations and 53,000 deaths, and is a likely
contributing factor in 265,000 deaths. The one-year
mortality rate of patients in Class III to IV of the New
York Hearth Association (NYHA) is nearly 40%. The
cost of medical treatment for HF has been projected
to be 27.9 billion dollars in the U.S. in 2005.
Cardiac transplantation is currently the only
established surgical treatment for refractory end-stage
HF (stage D), but it is available to fewer than 2500
patients in the United States each year. Other standard
treatments of HF are limited to measures that only
slow its progression or manage its symptoms, and
include various pharmacological therapies and surgical
interventions.
In preclinical studies, cell therapy has been shown
to regenerate myocardial cells in the injured or necrotic
myocardium, stimulate angiogenesis, and improve both
systolic and diastolic ventricular function. In patients
with myocardial infarction, autologous stem cell therapy
has been shown to stimulate angiogenesis, repair local
cardiac tissue, and improve cardiac function. In
patients with ischemic HF, this therapy has been
demonstrated to improve ejection fraction, heart
pumping action, quality of life, NYHA class, and
exercise capacity, and has recently been shown to
improve ejection fraction in patients with non-ischemic
cardiomyopathy as well. In both ischemic and non-
ischemic patients, bone-marrow-derived stem cell
therapy has been shown to be safe in terms of
arrhythmias and/or other adverse events.
Stem cells can be derived from three main sources:
adult tissues, e.g., bone marrow; blastocysts (embryonic
stem cells); and tissues of fetuses from terminated
ectopic pregnancies, elective abortions or spontaneous
miscarriages. Most cell therapy administered to HF
patients to date has been bone-marrow-derived adult
autologous stem cells. Human fetal-derived stem cells
(HFDSCs) are thought to be more pluripotent than adult
stem cells, i.e., the former can develop into a wider
range of specialized cells. Although HFDSCs have been
used to treat a variety of conditions (blood and immune
system disorders, spinal cord injuries, stroke, other
neurological and eye disorders, and diabetes, there have
been no reports of HFDSCs used in HF therapy.
Given the promising findings to date of autologous
stem cell therapy in HF patients, the possibly greater
differentiating potential of HFDSCs and their
successful application in treating a variety of other
disorders, this trial was designed to investigate the
safety and efficacy of HFDSC implantation for the
treatment of idiopathic cardiomyopathy.
Materials and methods
This was an open-label, single-arm, prospective,
clinical study performed at Luis Vernaza Hospital,
Guayaquil, Ecuador. The study was approved by the
Ethics Committee of the hospital, and informed
consents fully explaining the potential risks of the
surgical procedure and HFDSC transplantation were
obtained from the patients.
Patient Population. All patients were assessed at
baseline for biochemistry profile, CBC, coagulation
profile, electrocardiogram, chest X-ray, transthoracic
echocardiogram with General Electric Vivid 7 device,
cardiac catheterization with coronary angiogram to
exclude ischemic heart disease, 6-minute walk test
over a 30 meters flat surface, exercise tolerance test
under Naughton protocol modified, NYHA classifi-
cation and Minnesota CHF test.
Patients participating in the study met the following
inclusion criteria:
–AHA diagnostic criteria for dilated non-ischemic,
non-chagasic cardiomyopathy
–Ejection fraction < 35% by transthoracic
echocardiography
–NYHA functional class III or IV
–Bilirubin, creatinine, BUN, serum glucose, GOT,
GPT<2.5 times normal values
–Symptomatic despite optimal drug therapy for HF
Exclusion criteria included:
–Valvular heart disease requiring surgical treatment
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– Other concurrent life-threatening disease,
infectious disease, blood disease, diagnosis of epilepsy,
or positive on HIV or VDRL testing
– Intolerance or hypersensitivity to biological
substances
– Participation in another clinical trial
– History of drug or alcohol abuse, psychiatric
disturbances or suicide attempts in the past 2 years
– Renal failure needing dialysis
– White blood cell count <5,000  or >12,000,
hematocrit < 30%,  pulmonary thromboembolism within
6 months
– Mechanical ventilation support in last 10 days
– Morbid obesity
Patients who were initially included who were
noncompliant with the protocol (tests or treatments),
which were lost to follow-up, or who developed an
unrelated new illness were excluded from the study.
For each patient, preoperative medications (digoxin,
furosemide, spironolactone, Ace-Inhibitors or
Angiotensin Receptor Blockers and Beta- Blockers)
were maintained throughout the study and follow-up.
Stem Cells.HFDSCs were provided by the Institute
for Regenerative Medicine (IRM, Villa Nova, St. John,
Barbados), and processed and prepared by the Institute
for Problems of Cryobiology and Cryomedicine (IPCC)
in the Ukraine. IPCC obtains HFDSCs from fetuses
5-12 weeks gestation from legally consented, non-
compensated donors who have undergone terminated
ectopic pregnancies, elective abortions or spontaneous
miscarriages. The HFDSCs are prepared from
harvested fetal liver tissue under sterile conditions, and
undergo polymerase chain reaction (PCR) testing for
HIV, hepatitis B and C, mycoplasma, toxoplasmosis,
cytomegalovirus, herpes simplex I and II, rubella, and
Treponema pallidum; and culture tests for bacterial and
fungal contamination. The cell preparations are stored
in cryoperservatives at –196°C in liquid nitrogen. The
percentage of viable cells according to the IPCC
certification was 60%.
HFDSCs were shipped in a cyropreserved state at
–150 to – 196°C in Minishipper containers from IPCC
to Luis Vernaza Hospital for this study, and maintained
in this state until use. Just prior to the procedure, the
HFDSCs cells were thawed to room temperature and
in 9 patients diluted in 80 ml of saline solution at 37є C;
in one patient approached by minithoracotomy, the
dilution was in 15 ml. Each patient received 60-80
million HFDSCs according to the information issued
by the provider (The Institute for Regenerative
Medicine).
Anesthesia and Surgical Technique. Patients
were anesthetized with fentanyl 0.50 mcg/kg as a
premedication, Thiopental 2mg/kg as induction,
atracurium 1mg/kg for relaxation, and remifentanil
0.025 mcg/kg/min and sevofurane at 0.5-1.5% for
maintenance during the procedure. Nine patients had
midline sternotomy, and one had a left anterior
minithoracotomy in the fifth intercostal space. Prior to
the injections, 80 marks, 1 cm apart, were made with
a blue methylene marker on the anterolateral,
posterolateral, and diaphragmatic left ventricular wall,
and anterolateral right ventricular wall, avoiding
coronary blood vessels.
A total of 80 1 ml injections 3 mm deep were
administered by a 25-gauge needle with a catheter in
the marked areas. For the patient undergoing the
minithoracotomy (SB, female, 48 years), only 15
injections were made in the anterolateral wall. During
the procedure, patients were monitored for arterial
pressure, central venous pressure, urine output, EKG,
O2 saturation, and ETCO2. Potassium (20 mEq/hour)
and Magnesium (1g/hour) infusions were started before
the operations and maintained up to the chest closure.
All patients were extubated on the theater.
At 30, 90 and 210 days after the procedure, each
patient was reassessed for NYHA classification, ETT;
ejection fraction, LVEDD and 6-minutes walk test
performance. The Minnesota CHF test was performed
before the operation and at 210 days.
Statistical Analysis. Mean values for parameters
just before and after the procedure were compared
using paired t-tests (Primer program).
Results and discussion
Six female and 4 male patients (age range 47-77
years) met the inclusion criteria and participated in the
study. Five had functional impairment of NYHA class
IV and 5 were of class III.
There was no operative or perioperative mortality.
One male patient (UJ, 69 years), during the procedure
but before receiving injections, had a transient single
intraoperative ventricular fibrillation, which was
terminated by electrical cardioversion. One male (MJ,
66 years) and one female (VM, 77 years) required
temporary pacemakers postoperatively due to severe
bradycardia (<40 bpm), for 24 hours and 48 hours,
respectively. The former patient received dobutamine
for 24 hours. He also had a mild pericardial effusion at
3 weeks, which resolved spontaneously. He was later
excluded from the trial for non-compliance (abandoned
his controls) and he finally died at 5 months. The heart
autopsy showed nests of cardiomyocites among the
fibrotic tissue but it was not possible to determine
whether they were new myocardium growing or the
remaining native fibers. The immunochemistry search
of the heart showed the expression of the cell markers
CD 34, CD117, Actine smooth muscle, Vimentin and
Myogenin, and increased neovascularization in adjacent
fibrotic tissue. The electron microscopy did not clarify
if the new fibers were self-regenerating heart cells or
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due to the implants. Two Polymerase Chain Reactions
searches for chimerism were negative.
One female patient (QA, 52 years) had a right
hemiparesis 3 days after implantation due to ischemic
stroke, confirmed by CT scan. Although she was alive
and recovering as of this writing, she was excluded
from the protocol because she was unable to perform
the follow-up tests of the study.
Another female patient (BM), was hospitalized 3
times (at 2, 4 and 7 months) because of abdominal
pain due to severe gastroenteritis that led to transient
decompensation; she therefore required inotropic
support with dobutamine for 48, 48 and 72 hours
respectively. While there was no improvement in her
EF at 210 days, there was a significant improvement
in exercise tolerance test, LVEDD and 6 minute walk
test. At 210 days follow up, no other complications
were observed.
The 8 patients who provided 30-90 and 210 days
follow-up data demonstrated improvements clinically
and on imaging studies. With regard to imaging studies,
increased wall thickness both eccentric and concentric
was noted in association with an increased contractility
in those regions. Compared to baseline assessments,
patients improved in NYHA class (mean + SD: 3.4 +
0.5 to 1.9 + 0.6); LVEDD by transthoracic echocardio-
graphy decrease of 6mm (6.71 + 0.54 cm to 6.11 +0.58
cm, 8.94%, p= 0.001) ; Minnesota CHF score decrease
from 74 + 24 to 6+7; EF as assessed by transthoracic
echocardiography (26.6 + 4.0% to 34.8 + 7.2% a 31
% increase, (p=0.001); ETT from 4.25 min to 16.63
(291.3% increase, p= 0.0001) and 2.46 to 5.63 METS
(128.9 % increase, p= 0.0001), (Table 6); 6-minute
walk test : 251.0+113.1 seconds to 360.0+ 0  seconds,
a 43.42 % increase, (p = 0.003); average distance:
284.4+144.9 m to 468.2+ 89.8 m, a 64.4 % increase,
(p=0.007).
Current treatment options for refractory end-stage
HF are limited in effectiveness, and no current
treatment can totally repair ischemic or necrotic
myocardial tissue. Studies have suggested that
autologous stem cell therapy can be beneficial in
improving cardiac function in patients with HF due to
coronary diseases and, recently, in patients with non-
ischemic idiopathic cardiomyophathy. The preliminary
findings from this study constitute the first report of
the application of HFDSC therapy in HF patients. We
found statistically significant improvement in left
ventricular function (EF and LVEDD), NYHA class,
Exercise Tolerance Test, 6-minutes walk test
performance and Minnesota test 210 days following
direct myocardial cell implantation, including in the
patient who received the injection in the anterolateral
wall via minithoracotomy. All these patients were
maintained on their preoperative medications and doses
throughout the study.
It is worth noting that no new recurrent or permanent
arrhythmias were seen after implantation in this surgical
series of patients. As reviewed by others, arrhythmias
have been reported in studies of patients with HF or
myocardial infarction given skeletal myoblast cell
therapy, but this complication appears to be less of a
problem with autologous adult stem cells.
The improvements seen in our patients could have
been due to the administered HFDSCs or the surgical
procedure itself. Past studies with autologous adult
stem cells have shown ejection fraction improvements
in control groups given only plasma, however, the
improvements were small (5%). In the non-control
group in contrast, ejection fraction increased by as
much as 35%. The improvement seen in the present
cohort suggest that the HFDSCs have some therapeutic
effect. The mechanism of action as seen via
echocardiographic imaging suggests, however
preliminarily, that the increased wall thickness and
contractility in the regions described might be due to
an increase in the number of cardiomyocytes. More
studies are needed to validate this hypothesis and to
evaluate for the presence of a DNA from the donor.
Whether or not these cell markers expression and
the electron microscopy are showing if those
phenomena are constant or just appeared in a patient
who did not get as a good outcome as the rest of the
cohort remain as a question that also requires further
investigation to be answered.
We recognize that the relatively small number of
patients may represent a significant limitation of this
study. These initial findings, however, suggest that
HFDSC transplantation improves cardiac function in
HF patients early on and is sustained at 7 months. No
rejection reactions or malignancy were seen as of this
writing. We believe that given the sustained effect of
HFDSC therapy it indicates that offers another
possibility in treating advanced HF patients, and
represents a new approach that could be used before
other major surgical treatments, including heart
transplantation, due to their availability of having them
on the shelf avoiding the time consuming autologous
bone marrow harvesting and process. Irrespective of
the improvement seen in this trial, it is still premature
to determine accurately its mechanism of action,
indications and doses, so more research is needed
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